Official Title
Expanded Access Treatment With Open-Label Pegunigalsidase Alfa for Fabry Patients
Brief Summary

The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires treatment with enzyme replacement therapy (ERT) with pegunigalsidase alfa and a) cannot be adequately treated with currently approved FDA products and/or b) are not able or willing to participate in any of the on-going clinical trials in the United States.

Intermediate-size Population
Fabry Disease

Drug: Pegunigalsidase Alfa
Pengunigalsidase alfa is a recombinant ERT (enzyme replacement therapy) used to treat Fabry disease (dosage: 1 mg/kg body weight every 2 weeks).

Eligibility Criteria

Inclusion Criteria: - In the opinion of the Treating Physician, the patient cannot be adequately treated with any FDA approved drugs for Fabry and is not able to enroll in any current clinical trial for Fabry disease. - Patient (or legal guardian) is able to sign an informed consent prior to treatment. - A documented diagnosis of Fabry disease. - Preferably two, but at minimum 1, historical serum creatinine evaluations in the last 2 years with the latest value within the last 6 months. - Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically acceptable method of contraception, not including the rhythm method. Acceptable methods of contraception include hormonal products, intrauterine device, or male or female condoms. Contraception should be used for 90 days after treatment discontinuation.

Exclusion Criteria: - Patients enrolled and currently treated in Study PB-102-F20, and patients enrolled and currently treated in Extension Study PB-102-F60 - Patients who currently are on treatment under any other ongoing clinical trials of PRX-102 - History of Type 1 (anaphylaxis or anaphylactoid like) life-threatening hypersensitivity during previous exposure to other ERTs which could not be handled with medication - Women who are breastfeeding may not participate unless they agree to stop breastfeeding. - Women who are currently pregnant.

Eligibility Gender
Eligibility Age
Minimum: 18 Years
United States

University of Alabama-Birmingham
Birmingham, Alabama, 35294


Investigator: Eric Wallace

Phoenix Children's Hospital, Inc.
Phoenix, Arizona, 85006


Investigator: Jasmine Knoll

University of California Irvine
Orange, California, 92868


Investigator: Virginia Kimonis

Central Coas Nephrology
Salinas, California, 93901


Investigator: Barbara Rever

University of Florida, Division of Pediatric Genetics
Jacksonville, Florida, 32207


Investigator: Estella Mellin

Emory University School of Medicine
Atlanta, Georgia, 30322


Investigator: William Wilcox

University of Iowa
Iowa City, Iowa, 52242


Investigator: John Bernat

Infusion Associates
Grand Rapids, Michigan, 49525


Investigator: Khan Nedd

Dallas Nephrology Associates
Dallas, Texas, 75235-2208


Investigator: Ankit Mehta

University of Utah
Salt Lake City, Utah, 84108


Investigator: Nicola Longo

Lysosomal & Rare Disorder Research & Treatment Center (LRDRTC)
Fairfax, Virginia, 22030


Investigator: Ozlem Goker-Alpan


Medical Information Chiesi
(888) 661-9260

Chiesi USA, Inc.
NCT Number
Fabry disease
Pegunigalsidase alfa
MeSH Terms
Fabry Disease